Skip to main content

This Week in the British Journal of Cancer: May 31, 2011

Premium

In the British Journal of Cancer this week, researchers in the UK report on the difference in prognosis for breast cancer detected by screens and symptomatic breast cancer. The researchers analyzed 10-year survival data from more than 19,000 breast cancer patients, and found that survival in the screen-detected cases was 79.3 percent, compared with 62.8 percent in the symptomatic cases. "Our results suggested that a combination of lead time with size and node status in 10 categories explained almost all of the survival advantage," the researchers write.

Also in the British Journal of Cancer this week, researchers in Sweden and Germany say the PROX1 transcription factor is a novel predictor of survival in patients with grade II gliomas. PROX1 has been associated with both oncogenic and tumor-suppressive functions in human cancers. The researchers analyzed a total of 116 glioma samples and searched for the presence of the PROX1 protein. They found that higher PROX1 protein was associated with poor outcome, and that its presence can be used as a biomarker of survival.

Finally in the British Journal of Cancer this week, researchers in Japan present findings from a study of the association between cancer prognosis and the DNA-dependent protein kinase activity of peripheral blood lymphocytes. DNA-dependent protein kinase plays a role in the repair of DNA double-strand breaks. By studying 167 untreated cancer patients, the researchers found that DNA-dependent kinase activity in the peripheral blood lymphocytes of advanced cancer patients was significantly lower than in early-stage patients. Patients with lower kinase activity tended to have lower disease-specific survival rates, the authors write, and the kinase activity of most patients decreased in response to radiation treatments. "Cancer patients in advanced stage, with lower DNA-PK activity of peripheral blood lymphocytes might have higher distant metastasis and exhibit poorer prognosis," the team adds. "Therefore, DNA-PK activity in peripheral blood lymphocytes could be used as a marker to predict the chromosomal instability and poorer prognosis."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.